The American Academy of Pediatrics endorsed fecal transplants to eliminate a particular infection in children and called for more research about other uses.
Pediatric patients receiving a donor stem cell transplant who have healthier pretransplant gut microbiota diversity show improved rates of survival and a lower risk of acute GvHD.
Fecal microbiota transplant (FMT) promotes restoration of the gut microbiota, enzymes, and immune responses, and reduces ammonia build-up in patients with cirrhosis, a pilot study found.
Already successful in treating C difficile, fecal microbiota transplant could be applied to noncommunicable diseases, but better understanding of donor-recipient pairing is critical.